



(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 1/00 (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/EP2022/057029

(22) International Filing Date:

17 March 2022 (17.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/162,603 18 March 2021 (18.03.2021) US

(71) Applicant: **MEDIMMUNE LIMITED** [GB/GB]; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(72) Inventors: **NYS, Josquin Arnaud**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **THOM, Albert George**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **CARIUK, Peter**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **SCHOFIELD, Darren Jonathan**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **RILEY, Aidan**; MedImmune Limited, Milstein Building,


Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **HUNTINGTON, Catherine Eugenie Chaillan**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **REES, David Gareth**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **IRVING, Lorraine**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **ROBINSON, Matthew**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: THERAPEUTIC BINDING MOLECULE THAT BINDS TO CCR9

Figure 19



(57) Abstract: The invention relates to binding molecules, such as antibodies, that bind to the chemokine receptor CCR9. More particularly, the invention relates to the treatment of CCR9-mediated diseases or conditions such as inflammatory bowel disease (IBD), and methods for the detection of CCR9, which make use of the binding molecules of the invention.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(88) Date of publication of the international search report:

27 October 2022 (27.10.2022)